AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria. AbbVie and ...

AstraDx will receive $3 million to develop a test that detects and identifies pathogens and analyzes antimicrobial susceptibility in whole blood drawn from newborns.